Simultaneous inhibition of DNA-PK and Polϴ improves integration efficiency and precision of genome editing
Sandra Wimberger(AstraZeneca (Sweden)), Marcello Maresca(AstraZeneca (Sweden))
Cited by 116
Related Papers
Development of an ObLiGaRe Doxycycline Inducible Cas9 system for pre-clinical cancer drug discovery
|Nature Communications|2020|99
ObLiGaRe doxycycline Inducible (ODIn) Cas9 system driving pre-clinical drug discovery, from design to cancer treatment
|bioRxiv (Cold Spring Harbor Laboratory)|2020|3